<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>DIVAVACEHD Project</title>

<style>
body{
  font-family: Arial, sans-serif;
  background:#f6f7f8;
  margin:0;
  padding:40px 20px;
  color:#1f2933;
  line-height:1.65;
}

/* Contenedor */
.contenedor{
  max-width:900px;
  margin:auto;
  background:#ffffff;
  padding:40px;
  border-radius:14px;
}

/* Hero */
.hero{
  background:linear-gradient(180deg,#ffffff 0%,#f3f4f6 100%);
  padding:35px 25px;
  border-radius:12px;
  margin-bottom:40px;
}

/* Utilidades */
.centrado{text-align:center;}
.espacio{height:40px;}
strong{font-weight:700;}

/* Títulos */
.titulo{
  font-family:"Segoe UI", Arial, sans-serif;
  font-size:22px;
  max-width:750px;
  margin:25px auto;
}

h3{
  font-family:"Segoe UI", Arial, sans-serif;
  font-size:20px;
  margin-bottom:20px;
  padding-left:14px;
  border-left:4px solid #d1d5db; /* micro-línea */
}

/* Logos */
.logos{
  max-width:600px;
  margin:30px auto;
}
.logos img{
  height:60px;
  margin:15px;
  vertical-align:middle;
}

/* Sección */
.seccion{
  background:#fafafa;
  padding:30px;
  border-radius:12px;
  border:1px solid #e5e7eb;
}

/* Objetivos con badges */
.objetivos{
  list-style:none;
  padding-left:0;
}
.objetivos li{
  display:flex;
  align-items:flex-start;
  margin-bottom:16px;
}
.badge{
  min-width:30px;
  height:30px;
  border-radius:50%;
  background:#eef2f7;
  color:#374151;
  font-size:14px;
  font-weight:700;
  display:flex;
  align-items:center;
  justify-content:center;
  margin-right:14px;
  flex-shrink:0;
}

/* Separadores */
hr{
  border:none;
  border-top:1px solid #e5e7eb;
  margin:40px 0;
}

/* Footer */
.footer{
  font-size:13px;
  color:#6b7280;
  text-align:center;
  line-height:1.5;
}
</style>

</head>

<body>

<div class="contenedor">

  <div class="hero centrado">
    <img src="css/images/logo-principal.png" style="height:65px;">
    <br><br>
    <a href="index.html">ES</a> | <a href="en.html">EN</a>

    <p class="titulo"><strong>
      DEVELOPMENT OF A DIVA SUBUNIT VACCINE AGAINST EPIZOOTIC HEMORRHAGIC DISEASE (EHD) IN CATTLE PRODUCED USING CRISBIO® TECHNOLOGY
    </strong></p>

    <p><strong>Funded by CDTI</strong></p>

    <div class="logos">
      <img src="css/images/aei.png">
      <img src="css/images/cdti.png">
    </div>
  </div>

  <p><em>
    This project has been funded by CDTI and AEI, supported by the Spanish Ministry of Science and Innovation, within the framework of the State Plan for Scientific, Technical and Innovation Research (PEICTI), with the aim of promoting technological development, innovation and high-quality research.
  </em></p>

  <div class="logos">
    <img src="css/images/bbglobal.png">
    <img src="css/images/proalt.png">
    <img src="css/images/algenex.png">
    <img src="css/images/farmalan.png">
  </div>

  <hr>

  <div class="seccion">
    <h3>Objectives</h3>

    <p>
      <strong>The main objective</strong> of the project is to develop a safe and effective DIVA subunit vaccine against epizootic hemorrhagic disease in cattle (EHDV serotype 8).
    </p>

    <ul class="objetivos">
      <li><span class="badge">1</span>Validation of protection results in cattle.</li>
      <li><span class="badge">2</span>Development of the industrial antigen production process.</li>
      <li><span class="badge">3</span>Development of analytical and diagnostic tools.</li>
      <li><span class="badge">4</span>Structural and formulation studies.</li>
      <li><span class="badge">5</span>Production of regulatory banks and batches.</li>
      <li><span class="badge">6</span>Execution of clinical trials and preparation of the regulatory dossier.</li>
    </ul>
  </div>

  <hr>

  <div class="footer">
    <p>© 2026 DIVAVACEHD Consortium — BBGlobal, ProAlt, Algenex and Farmalan.</p>
    <p>Project funded by CDTI and AEI, with support from the Spanish Ministry of Science and Innovation.</p>
    <p>This website is for informational purposes only.</p>
  </div>

</div>

<script src="https://counter.websiteout.com/js/36/0/0/0"></script>

</body>
</html>
